As cancer stem cells are known for their intrinsic resistance to chemotherapy and radiation, it is reasonable to expect that CD44-positive cells (CSCs) exhibit higher resistance to conventional therapies than CD44-negative cells (non-CSCs) within the tumor. The gene discussed is CD44; the disease is cancer.